Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis
Arthritis & Rheumatism2008Vol. 58(10), pp. 2993–2999
Citations Over TimeTop 1% of 2008 papers
Abstract
This study is the first to show, using a highly sensitive analysis, that rituximab therapy is associated with variable diminution in B cell numbers. A lack of complete depletion of B cells after 1 infusion was associated with a poorer outcome.
Related Papers
- → Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab(2017)34 cited
- Rituximab for ANCA-associated vasculitides.(2014)
- [Rituximab for managing refractory thrombotic thrombocytopenic purpura: a report of three cases].(2013)
- → A COMMON ERROR IN USING COMBINED TREATMENT WITH RITUXIMAB AND PLASMAPHERESIS (PP) TO PREVENT OR TREAT ANTIBODY MEDIATED REJECTION (AMR)(2020)
- [Long-term prognosis of patients with steroid-dependent nephrotic syndrome treated with rituximab].(2013)